Listed in Penny Stocks, Stock Picks, StockGuru.com, Day Trading, Best Stocks

WEST HAVEN, Conn.–(BUSINESSWIRE)

NanoViricides, Inc. (OTCBB: NNVC.OB)
(the “Company”) reports that post-infection treatment with its optimized
FluCide™ drug candidates achieved 1,000-fold reduction in the levels of
infectious virus in the lungs of animals with a lethal level of
influenza virus infection. These findings corroborate the previously
reported findings of both increased animal survival and protection of
the lungs from influenza virus tissue damage in FluCide-treated animals
in the most recent H1N1 influenza study.

The amount of infectious virus in the lungs of the infected animals
treated with three of the optimized FluCide™ nanoviricide drug
candidates was reduced by greater than 1000-fold as compared to the
infected untreated control animals (p-values

Penny Stocks are stocks traded for under $2 and they represent the small cap companies. They trade on the OTCBB so you will not find them on the major stock exchanges. They are very cheap stocks and normally come for businesses needing capital. They are a very risky investment as the business can go under and leave you with a stock worth nothing. However that being said penny stock trading can be a great money maker, and there are numerous traders who make 6 figures and more from them each year.

The best reasons to trade in penny stocks are the fact that they do not require a large initial investment, meaning that they are an affordable investment for many. Penny stocks are cheap. For example if you were to buy 1000 shares in a company with shares at 10 cents, you would only require an investment of $100, whereas if the shares cost $5 you would require an investment of $5000. Penny stocks also have the potential of huge gains, and have been known to rise as much as 1000% daily. Therefore your $100 investment can be worth $1000. This is very unlikely to happen to other stocks from large cap businesses.

 

Article source: http://uk.finance.yahoo.com/news/Treatment-NanoViricides-businesswireuk-3087397277.html?x=0